Our Product Development Pipeline
Our robust product development pipeline is built on a portfolio of proprietary and patented technology. Driven by Lisata’s vision and mission, our pipeline programs are grounded in rational science to identify and treat patients most likely to respond to our targeted therapies. Click on each program to learn more.
CendR Platform® Programs
The CendR Platform® incorporates novel technologies to enable more effective tumor-targeted, tissue penetrating delivery of anti-cancer agents to solid tumors. The Platform can also target non-cancerous, immunosuppressive cells selectively within the tumor to enable a patient’s immune system and/or immunotherapies to fight cancer more effectively.
Indication | Pre Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Indication: First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) |
||||
Gemcitabine/nab-paclitaxel with LSTA1 or placebo (Australia/New Zealand) | ||||
First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) |
Gemcitabine/nab-paclitaxel with LSTA1 or placebo (Australia/New Zealand)
|
|
Phase 2
|
|
Gemcitabine/nab-paclitaxel + LSTA1 (China) | ||||
Gemcitabine/nab-paclitaxel + LSTA1 (China)
|
Phase 1
|
|
|
|
Durvalumab, gemcitabine/nab-paclitaxel + LSTA1 (Australia) | ||||
Durvalumab, gemcitabine/nab-paclitaxel + LSTA1 (Australia)
|
Phase 1
|
|
|
|
Indication: Pancreatic, Colon, and Appendiceal Cancers |
||||
LSTA1 + FOLFIRINOX + panitumumab* (U.S.) | ||||
Pancreatic, Colon, and Appendiceal Cancers |
LSTA1 + FOLFIRINOX + panitumumab* (U.S.)
|
Phase 1
|
|
|
Indication: Various Solid Tumors |
||||
SoC with LSTA1 or placebo (U.S.) | ||||
Various Solid Tumors |
SoC with LSTA1 or placebo (U.S.)
|
|
Phase 2
|
|
CD34+ Platform Programs
Lisata’s proprietary CD34+ cell technology has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Through the administration of CD34+ cell therapy, the Company seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted areas.
Indication | Pre Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Indication: Coronary Microvascular Dysfunction |
||||
XOWNA® (LSTA16) (U.S.) | ||||
Coronary Microvascular Dysfunction |
XOWNA® (LSTA16) (U.S.)
|
|
Phase 2
|
|
Indication: Critical Limb Ischemia and Buerger’s Disease |
||||
HONEDRA® (LSTA12) (Japan) | ||||
Critical Limb Ischemia and Buerger’s Disease |
HONEDRA® (LSTA12) (Japan)
|
|
Phase 2
|
|
Indication: Diabetic Kidney Disease |
||||
LSTA201 (U.S.) | ||||
Diabetic Kidney Disease |
LSTA201 (U.S.)
|
Phase 1
|
|
|